Greenwich LifeSciences, Inc. (GLSI) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Exchange
- XNAS
- Market Cap
- $0.4B
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +5.00% | 6 |
| Feb | -3.84% | 6 |
| Mar | +1.77% | 6 |
| Apr | -15.56% | 6 |
| May | -3.93% | 5 |
| Jun | +4.76% | 5 |
| Jul | -2.13% | 5 |
| Aug | +1.37% | 5 |
| Sep | -2.60% | 5 |
| Oct | -3.92% | 5 |
| Nov | +17.32% | 5 |
| Dec | +34.40% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 49.5 | Neutral |
| MACD | 0.279 | Bearish |
| Bollinger Bands | Neutral | |
| ADX | 14.6 | Range |
| HV 30 | 95.8% |
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2026-04-20 | Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 | GlobeNewswire Inc. | |
| 2026-04-07 | Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential | GlobeNewswire Inc. | |
| 2026-03-19 | Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 | GlobeNewswire Inc. | |
| 2026-03-18 | Greenwich LifeSciences Provides Update on Upcoming AACR Meeting | GlobeNewswire Inc. | |
| 2026-03-16 | Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 | GlobeNewswire Inc. | |
| 2026-03-03 | Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 | GlobeNewswire Inc. | |
| 2026-02-24 | Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 | GlobeNewswire Inc. | |
| 2026-01-27 | Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy | GlobeNewswire Inc. |
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 2.47
- Correlation (SPY)
- 36.6%
- R²
- 0.13
- Ann. Volatility
- 88.6%
- SPY Volatility
- 13.1%
High volatility - stock moves more than market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.